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FDG PET-CT imaging detects arterial
inflammation and early atherosclerosis in
HIV-infected adults with cardiovascular disease
risk factors
Kevin E Yarasheski1,6*, Erin Laciny1, E Turner Overton2, Dominic N Reeds3, Michael Harrod4, Steven Baldwin4 and
Victor G Dávila-Román5

Abstract
Background: Persistent vascular inflammation has been implicated as an important cause for a higher prevalence
of cardiovascular disease (CVD) in HIV-infected adults. In several populations at high risk for CVD, vascular
18
Fluorodeoxyglucose (18FDG) uptake quantified using 3D-positron emission-computed tomography (PET-CT) has
been used as a molecular level biomarker for the presence of metabolically active proinflammatory macrophages in
rupture-prone early atherosclerotic plaques. We hypothesized that 18FDG PET-CT imaging would detect arterial
inflammation and early atherosclerosis in HIV-infected adults with modest CVD risk.
Methods: We studied 9 HIV-infected participants with fully suppressed HIV viremia on antiretroviral therapy (8 men,
median age 52 yrs, median BMI 29 kg/m2, median CD4 count 655 cells/μL, 33% current smokers) and 5 HIVnegative participants (4 men, median age 44 yrs, median BMI 25 kg/m2, no current smokers). Mean Framingham
Risk Scores were higher for HIV-infected persons (9% vs. 2%, p < 0.01). 18FDG (370 MBq) was administered
intravenously. 3D-PET-CT images were obtained 3.5 hrs later. 18FDG uptake into both carotid arteries and the aorta
was compared between the two groups.
Results: Right and left carotid 18FDG uptake was greater (P < 0.03) in the HIV group (1.77 ±0.26, 1.33 ±0.09 target
to background ratio (TBR)) than the control group (1.05 ± 0.10, 1.03 ± 0.05 TBR). 18FDG uptake in the aorta was
greater in HIV (1.50 ±0.16 TBR) vs control group (1.24 ± 0.05 TBR), but did not reach statistical significance (P = 0.18).
Conclusions: Carotid artery 18FDG PET-CT imaging detected differences in vascular inflammation and early
atherosclerosis between HIV-infected adults with CVD risk factors and healthy HIV-seronegative controls. These
findings confirm the utility of this molecular level imaging approach for detecting and quantifying glucose uptake
into inflammatory macrophages present in metabolically active, rupture-prone atherosclerotic plaques in HIV
infected adults; a population with increased CVD risk.
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Background
Atherosclerosis is initiated by a series of proinflammatory
events that occur in the arterial wall causing endothelial
smooth muscle disruption, macrophage activation and
infiltration, oxidized lipid accumulation, and plaque formation [1-6]. Several circulating and imaging biomarkers
for these proatherogenic processes have been assessed
clinically [7-14]. Unfortunately, few are specific for early
molecular level events involved in atherogenesis. Thus,
they are not predictive biomarkers of subclinical atherosclerosis that identify people at early risk for developing
vascular plaques. Moreover, none of these biomarkers
provides information about the risk for plaque rupture or
thrombosis that result in infarct or stroke.
People living with human immunodeficiency virus
infection (HIV) have a 2-fold greater risk for experiencing a stroke or myocardial infarction than the general
population [15-17]. Evidence suggests that chronic
low-grade inflammation associated with the host immune response to HIV infection and ongoing viral
replication contributes to greater cardiovascular disease (CVD) risk and the higher incidence of CV events
in HIV infected adults [18-23]. However, the evidence
is based primarily on circulating biomarkers for inflammation (hsCRP, D-dimer, cytokines) which are neither sensitive, nor specific molecular-level predictive
biomarkers for early proatherogenesis or vascular
plaque in/stability [21,24].
Several groups have pioneered the use of 18Fluorodeoxyglucose (18FDG) uptake by proinflammatory
macrophages present in the arterial wall as a noninvasive, sensitive, specific, and reproducible molecular
level biomarker for early atheroma formation in metabolically active, rupture-prone atherosclerotic plaques
[25-51]. Proinflammatory macrophages utilize glucose at
a high rate [30,40,49], and 3-dimensional positron
emission-computed tomography imaging (PET-CT)
detects 18FDG uptake by macrophages in the vascular
wall of animals and humans. 18FDG PET-CT imaging
has been used to detect and quantify vascular inflammation in early atherogenesis and in vulnerable plaques in
human aorta and carotid arteries, but not in people living with HIV and asymptomatic CVD.
The purpose of this proof-of-concept pilot study was
to determine if 18FDG PET-CT imaging detects greater
aortic and carotid inflammation and early atherosclerosis
in HIV-infected adults with mild CVD risk and known
carotid plaque than in healthy controls without significant CVD risk. If confirmed, 18FDG PET-CT can be used
to monitor atherogenesis, determine the independent
contributions of HIV infection and anti-retroviral therapy to vascular inflammation, and evaluate the antiinflammatory, anti-atherogenic effectiveness of therapeutic interventions in people living with HIV.
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Participants

Healthy men and women were recruited from Washington University Institute of Clinical and Translational
Sciences Research Participant Registry. Inclusion criteria
were: 35–60 yrs old, confirmed HIV seronegative status,
fasting plasma glucose <100 mg/dL and <140 mg/dL
two hours after ingesting a 75-gr glucose beverage, fasting serum triglycerides <150 mg/dL, HDL-cholesterol
>40 mg/dL (men), >50 mg/dL(women), resting blood
pressures <130/85 mmHg), carotid intima media thickness <0.8 mm and no evidence for carotid plaque, waist
circumference (at the umbilicus) <102 cm (men,
<88 cm (women). Exclusion criteria were: known cardiac or cerebrovascular disease, kidney or liver disease
(active hepatitis B or C), certain medications (e.g.,
glucose- or lipid-lowering agents, anti-hypertensives, low
dose aspirin, or other anti-inflammatory agents), illegal
drug use (cocaine, methamphetamines, opiates detected
on urine drug screen), pregnancy, cognitive impairment
that limited their ability to provide voluntary informed
consent, incarcerated or otherwise unable to provide
informed consent. We excluded younger adults because
the prevalence of atherosclerosis is rare in people
<35 yrs old. Before screening, healthy controls were
informed that participation required a test for HIVinfection and the implications of a positive HIV test.
HIV infected men and women were recruited from the
Washington University AIDS Clinical Trials Unit and
Infectious Diseases Clinics. Inclusion criteria were: 35–
60 yrs old, documented HIV seropositive status, stable
antiretroviral therapy for at least the past 4 months,
CD4+ T-cell count >200 cells/μL, plasma HIV RNA
<50 copies/mL, fasting plasma glucose 100–126 mg/dL,
or 140–200 mg/dL two hours after ingesting 75-gr glucose beverage, or fasting triglycerides >150 mg/dL,
HDL-cholesterol <40 mg/dL (men), <50 mg/dL
(women), or resting blood pressure ≥130/85 mmHg, carotid intima media thickness >0.8 mm or evidence of
carotid plaque, or waist circumference ≥102 cm(men),
≥88 cm(women), or BMI 25–35 kg/m2. Exclusion criteria were identical to those used for the healthy controls. By enrolling two groups with distinctly different
cardiometabolic phenotypes, we optimized our chances
of detecting a difference in arterial inflammation.
We enrolled 9 HIV infected adults with cardiovascular
disease (CVD) risk factors and documented (ultrasound)
carotid intima media thickening or non-obstructive
plaque, and 5 HIV seronegative adults with no CVD risk
factors (Table 1). Right and left carotid 18FDG PET-CT
studies were conducted on all 14 participants. Aorta
18
FDG PET-CT studies were added after the first five
participants were enrolled, so aorta 18FDG studies were
conducted on 4 controls and 5 HIV participants. All participants provided verbal and written informed consent.
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Table 1 Physical and Demographic Characteristics
Parameter

Control

HIV+

p-value

N (% female)

5 (20)

9 (11)

1.0

Ethnicity

All Caucasian

7 Cauc. 2 African American

0.51

Age (yrs)

44 ± 3 (46, 35, 51)

52 ± 3 (52, 38, 67)

0.07
<0.01

# Yrs Known HIV+

0

14 ± 2 (13, 7, 20)

CD4+ (cells/μL)

nd

771 ± 132 (655, 622, 1035)

Plasma HIV RNA (copies/mL)

nd

All <50

History Hypertension (%)

0

78

0.02

Family History Diabetes (%)

0

56

0.08

History Hyperlipidemia (%)

20

44

0.58

Current tobacco smoker (%)

0

33

0.26

# Yrs Smoker

0

21 ± 4 (22, 10, 30)

<0.01

Packs/day

0

1.4 ± 0.2 (1.3,1.0,2.0)

<0.01

BMI (kg/m2)

25 ± 1 (25, 20, 28)

29 ± 2 (26, 22, 40)

0.12

Waist circ (cm)

86 ± 3 (88, 79, 90)

101 ± 6 (95, 84, 130)

0.07

Resting Systolic BP (mmHg)

112 ± 3 (114,104,119)

129 ± 5 (128, 115, 150)

0.01

Resting Diastolic BP (mmHg)

71 ± 5 (72, 55, 88)

76 ± 3 (75, 66, 90)

0.48

Fasting Triglycerides (mg/dL)

63 ± 6 (60, 53, 79)

149 ± 35 (115, 43, 349)

0.04

HDL-cholesterol (mg/dL)

51 ± 6 (50, 37, 65)

45 ± 4 (47, 29, 68)

0.43

Total cholesterol (mg/dL)

164 ± 4 (164, 156, 172)

182 ± 9 (177, 140, 218)

0.11

Calc.LDL-cholesterol (mg/dL)

101 ± 7 (95, 91, 122)

108 ± 9 (106, 74, 156)

0.55

Framingham 10-yr Risk

2 ± 1 (1, 1, 4)

9 ± 2 (7, 1, 18)

<0.01

Mean Right & Left Posterior CIMT (mm)

0.54 ± 0.03 (0.52, 0.45, 0.63)

0.78 ± 0.02 (0.78, 0.66, 0.90)

<0.01

Non-obstructive Plaque

0

8 (89%)

Carotid Ultrasound

Glycemic Control
Fasting Glucose (mg/dL)

89 ± 3 (89, 81, 96)

97 ± 4 (98, 82, 114)

0.11

Fasting Insulin (μU/mL)

2.0 ± 0.1 (2, 2, 2)

13.7 ± 4.5 (9, 6, 30)

0.06

Fasting C-peptide (ng/mL)

0.9 ± 0.1 (0.9, 0.7,1.0)

4.0 ± 0.8 (3.4, 2.3, 6.5)

0.02

HOMA

0.4 ± 0.0 (0.4, 0.4, 0.5)

3.2 ± 1.1 (2.6, 1.2, 7.4)

0.07

hs-CRP (mg/L)

0.8 ± 0.3 (0.8, 0.5, 1.2)

2.6 ± 2.3 (2.0, 0.6, 6.2)

0.16

D-dimer (μg FEU/mL)

0.1 ± 0.1 (0.1, 0.0, 0.2)

0.4 ± 0.5 (0.1, 0.0, 1.1)

0.27

Systemic Inflammatory Biomarkers

Mean ± SE (Median, Min, Max); CIMT = carotid intima media thickness; nd = not done.

The informed consent document was approved by the
Human Research Protection Office and the Radioactive
Drug Research Committee at Washington University
School of Medicine. The study was registered with ClinicalTrials.gov (#00958815).

Methods
Carotid ultrasound imaging

Carotid artery intima-media thickness (CIMT) was measured by a single vascular sonographer using B-mode
images of both carotid arteries expressed as the average

thickness of the far walls of the right and left common
carotid arteries; each site represents the average of 3
separate measurements [7]. The intra-class correlation
coefficient for repeated measures of the CIMT is 0.91 at
our laboratory [52]. The presence of carotid plaque was
defined as described [7]; focal wall thickening that was
≥50% of the surrounding vessel wall or as a focal region
with CIMT >1.5 mm that protruded into the lumen and
was distinct from the adjacent boundary. Carotid wall
thickening that did not meet this definition (<50% or
<1.5 mm) was classified as a non-obstructive plaque.
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18

FDG PET-CT imaging

After an overnight fast, 18FDG (~370 MBq;
9.9 ± 0.5 mCi) was administered intravenously and 3.5 hr
later, 3D-PET-CT images of the thoracic ascending, arch,
and descending aorta and carotid arteries were obtained.
Prior to 18FDG administration, fasting blood glucose
concentration was measured; if >150 mg/dL the scan
was rescheduled. To minimize motion artifact during
image acquisition, each participant was individually fitted with a thermoplastic mask (Orfit Industries America,
Jericho, NY) that was secured to the scanner table and
immobilized their head, neck and shoulders.
A Biograph 40 Truepoint PET-CT scanner (Siemens,
Malvern, PA) was used to acquire 3-dimensional neck
and chest CT attenuation and contrast CT scans. The
PET used lutetium oxyorthosilicate detectors (169 crystals/detector block, 192 detector blocks, 52 detector
rings) and a 216 mm axial field of view (FOV). The
CT has 40 detector rows and a 700 mm transaxial
extended FOV. The CT attenuation scans used low
dose CT (30 mAs (eff.), 120 kV, 0.5 sec rotation, 0.8
pitch, 28.8 mm collimation, 3 mm slice thickness,
500 mm transaxial FOV).
PET images were obtained at 2 bed positions (15 min
per position) and both attenuation corrected and nonattenuation images were reconstructed in a 168 x 168
pixel matrix. Attenuation corrected PET images were
reconstructed with ordered subset method of the expectation maximization (OSEM) using 4 iterations, 8 subsets
and Gaussian filter 5 mm Full Width Half Maximum
(FWHM). Only CT attenuated PET volumes were used
for analysis. Contrast CT images were obtained immediately after the PET images were obtained. Contrast CT
used 150 mAs (eff.), 120 kV, 0.5 sec rotation, 1.0 pitch,
28.8 mm collimation, 3 mm slice thickness, 500 mm
transaxial FOV. Immediately prior to acquiring contrast
CT images, 70 mL of Isovue-370 (Bracco Diagnostics,
Princeton, NJ) were infused intravenously. The contrast
agent clearly delineated the narrow carotid arteries and
jugular veins, and optimized CT and PET image coregistration and analysis.
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calculate the maximum target-to-background ratio
(TBRmax) in both carotid arteries and the aorta.
Specifically, PET volumes were converted to body
weight standardized uptake values (SUVbw), where,
1 mL pure water = 1gr of body weight. In both regions of
interest (neck, upper chest), axial PET and CT volumes
were cropped to focus and reduce the dataset sizes.
Within each axial image, rigid anatomical landmarks
were identified (neck = cervical vertebrae; upper chest =
sternum) and used to align the contrast CT volume with
corresponding PET and CT attenuation volumes. Affine
volume transformation by normalized cross correlation
that allowed for rotation and shift in all three planes was
used to register the contrast CT scan with the CT attenuation scan using the nearest rigid (bone) landmark
corresponding to the vessel of interest. The contrast CT
and CT attenuation co-registration matrix obtained was
then used to align the corresponding PET volume. This
provided optimal PET volume co-registration with contrast CT-enhanced vascular anatomy. MATLAB functions then quantified 18FDG SUV metrics (mean,
median, standard deviation, min, max) along the arterial
and venous regions, and these were used to derive carotid and aorta TBRmax [28].
Serum lipids and lipoproteins

Blood was collected from an antecubital vein after a 1012 hr overnight fast. As described [53], serum triglycerides, total- and HDL-cholesterol were measured and
LDL-cholesterol estimated in the Core Laboratory for
Clinical Studies at Washington University Medical Center. The accuracy of these methods is verified and standardized by participation in the Centers for Disease
Control (CDC) Lipid Standardization Program, the CDC
Cholesterol Reference Method Laboratory Network, and
the College of American Pathologists external proficiency program [54]. Framingham 10-yr coronary heart
disease (CHD) risk was determined using an American
Heart Association calculator (http://hp2010.nhlbihin.
net/atpiii/calculator.asp?usertype=prof ).
Blood hormones and metabolites

PET-CT image analysis

Image analysis was conducted using custom extensions of
MATLAB (The Mathworks Inc., Natick, MA). All images
were analyzed by the same analyst (blinded to group assignment) using a standardized workflow. In general,
MATLAB functions were used to co-register PET, CT attenuation and contrast CT images/datasets, quantify maximum 18FDG uptake (SUV) within the vessels from 1 cm
above to 1 cm below the right and left carotid bifurcation,
and through the ascending, arch, and descending aorta.
Background 18FDG uptake in corresponding regions of
the jugular veins and superior vena cava were used to

As described [55], plasma glucose concentration was
quantified using an automated YSI glucose analyzer
(Yellow Springs Instruments, Yellow Springs, OH), and
plasma insulin and C-peptide concentrations were determined using chemiluminescent immunometric methods
(Immulite; Siemens, Los Angeles, CA). The homeostasis
model assessment of insulin resistance (HOMA) was
calculated as described [56].
Systemic inflammatory biomarkers

D-dimer and highly sensitive C-Reactive Protein (hsCRP)
concentrations were quantified using particle enhanced
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immuno-turbidimetric assay kits according to manufacturer’s instructions (Roche Diagnostics, Indianapolis,
IN). Human plasma CRP and D-dimer complex with
latex particles coated with a monoclonal antibody directed against CRP or D-dimer epitopes, and the precipitate
was assayed for turbidity on a Roche/Hitachi Cobas c
system. Adequate amounts of archived plasma from 4
healthy controls and 5 HIV participants were available
for these assays.
Data analysis

Mean ± standard error (SE), median, minimum and maximum values are reported for the participant characteristics. Physical and demographic characteristics were
compared using a non-parametric Fishers’ exact test or
Kruskal–Wallis one-way analysis of variance by ranks
test. Carotid and aorta maximum TBRmax were compared between groups using an unpaired t-test. P < 0.05
was accepted as significant.

Results
The two groups had similar demographic characteristics
(age, sex, ethnicity; Table 1). Mean and median age for
HIV + participants (Mean ± SE; 52 ± 3 yrs, median =
52 yrs) were numerically, but not statistically higher
(p = 0.07) than controls (44 ± 3 yrs, median =46 yrs).
Immune (CD4+ T-cell count = 771 ± 132 cells/μL) and
virologic (all <50 copies HIV RNA/mL) status were
stable and controlled in the HIV + participants. By design, cardiovascular disease risk profiles were worse
among HIV + participants than controls (Table 1). The
Framingham 10-yr coronary heart disease (CHD) risk
score was greater (9 ± 2%) in HIV + participants than in
controls (2 ± 1%; p < 0.01), but by definition these represent low (<10%) risk for CHD events (MI, stroke). Four
of the 9 HIV participants had Framingham 10-yr CHD
risk scores between 10-20%. The higher CHD risk score
among HIV + participants was attributed to current
tobacco use and higher systolic blood pressure (history
of hypertension).
The mean intima media thickness of the common carotid arteries was greater (p < 0.01) in HIV + participants
(0.78 ± 0.02 mm) than controls (0.54 ± 0.03 mm), and
eight of nine HIV + participants had ultrasound detectable non-obstructive plaques in at least one carotid artery, while no plaques were detected in controls.
Glycemic control parameters (fasting glucose, insulin, Cpeptide, HOMA) were not different between control and
HIV + participants. Fasting triglycerides were greater
(p = 0.04) in HIV + participants (149 ±35 mg/dL) than
controls (63 ± 6 mg/dL), but total-, HDL-, and calculated
LDL-cholesterol levels were not different between
groups. D-dimer and hsCRP levels were numerically, but
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not statistically (P > 0.16), higher in HIV + participants
than controls.
Representative images of carotid 18FDG PET uptake
superimposed on the contrast CT images, and the corresponding carotid ultrasound images are provided for an
HIV + and a control participant (Figure 1). Right and left
carotid 18FDG uptake (TBRmax) was greater (P < 0.03) in
HIV + participants (1.77 ±0.26, 1.33 ±0.09) than controls
(1.05 ± 0.10, 1.03 ± 0.05; Figure 2). Aorta 18FDG TBRmax
tended (P = 0.18) to be greater in HIV + participants
(1.50 ± 0.16) than controls (1.24 ±0.05; Figure 2).

Discussion
Carotid artery 18FDG PET-CT imaging detected differences in vascular inflammation and early atherosclerosis
between HIV-infected adults with CVD risk factors and
healthy HIV-seronegative controls. These findings confirm the utility of this molecular level imaging approach
for detecting and quantifying glucose uptake into inflammatory macrophages present in metabolically active,
rupture-prone atherosclerotic lesions or early nonobstructive plaques in HIV infected adults; a population
with increased CVD risk.
Vascular inflammation has been implicated in the
underlying pathophysiology for the higher incidence of
myocardial infarction and stroke in HIV infected adults
taking anti-retroviral medications. However, this suggestion is based on indirect, non-specific measures of
circulating pro-inflammatory or pro-oxidant stress biomarkers, or static vascular imaging methods (carotid
intima media thickness, coronary calcium deposition).
We provide the first direct, molecular-level evidence
for the presence of metabolically active, inflammatory
vascular lesions/plaques in people living with HIV infection. It is important to note that the HIV participants studied had modest clinical evidence of CVD
risk; characterized by carotid intima media thickening
or small non-obstructive plaques and low Framingham
10-yr CHD risk profiles (9 ± 2% risk). However, carotid
18
FDG PET-CT imaging and greater TBRmax provided
clearer evidence of atherosclerotic vascular disease in
HIV + participants.
We specifically selected participants with ultrasounddetected carotid intima media thickening and nonobstructive plaques in order to assess the ability of vascular 18FDG PET-CT imaging to detect an expected difference in vascular inflammation between healthy
controls and HIV-infected men and women with CHD
risk. In agreement with others, we found that not all calcified lesions are metabolically active, inflammatory,
rupture-prone plaques [25,26]. The current study was
underpowered to definitively assess the relationship between 18FDG uptake and carotid thickness. The
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Panel 1. Control
Transverse
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Sagittal

Coronal

Sagittal

Coronal

Carotid Ultrasound

A

B

Panel 2. HIV+
Transverse

Carotid Ultrasound

A

B

Non-obstructive plaque
in posterior wall

cIMT
thickening
in anterior
and posterior
walls

Figure 1 Representative co-registered 3-dimensional positron emission (PET) and contrast-enhanced computed tomography (CT)
images of the right carotid artery of a healthy HIV-seronegative control male (Panel 1), and an HIV infected man with CVD risk factors
(Panel 2). Transverse, sagittal, and coronal contrast CT images (A) and PET 18FDG uptake images (B) along with the corresponding carotid
ultrasound images for these two men are shown. The anterior wall of the right carotid artery (upper portion of the carotid ultrasound image) is
indicated with a yellow arrow and the posterior wall with a red arrow (lower portion of the image). In the HIV infected man (Panel 2), ultrasound
imaging detected increased carotid artery intima media thickness in both the anterior and posterior walls and a non-obstructive plaque in the
posterior wall of the right carotid artery. In the healthy control male (Panel 1), the intima media thickness was normal and no plaques were
present in the anterior or posterior walls of the right carotid artery. Carotid PET imaging detected regions of higher 18FDG uptake (red nodules in
blue, red and green ovals) in the HIV infected man (Panel 2B), while less 18FDG uptake was detected in the carotid artery of the healthy control
male (Panel 1B).

relationship between plaque morphology and 18FDG uptake should be further investigated in future studies.
This imaging method may be useful for addressing
several critically important clinical questions in HIV
infected people, e.g., Is there vascular inflammation in
untreated HIV-infection? Does highly active antiretroviral therapy reduce or worsen vascular inflammation? Is vascular inflammation worse in older
HIV-infected adults than in age- and CVD risk
factor-matched HIV-seronegative adults? Do effective
treatments for insulin resistance, dyslipidemia, or antiinflammatory agents reduce vascular inflammation in
HIV? In the long-term, does a reduction in vascular inflammation translate to fewer clinical events (stroke, MI)
in HIV? This non-invasive method is ideal for examining
interactions among vascular inflammation and CVD risk
factors (insulin resistance, central obesity, dyslipidemia)
on early atherosclerotic progression in HIV and other
autoimmune disorders where inflammatory stimuli are

implicated (e.g., systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease).
Circulating inflammatory biomarker levels (hsCRP, Ddimer) were variable, but on average, were 3–4 times
higher in HIV than healthy controls. This supports the
generalization that even well-controlled HIV (using contemporary anti-viral agents) is associated with a chronic,
low-grade, pro-inflammatory state, but the stimulus,
source, location and severity of the inflammation cannot
be discerned from these plasma biomarkers. HIV related
inflammation can be caused by multiple factors, including chronic replicating virus, anti-HIV medications, gut
microbial translocation, obesity, diabetes, tobacco/alcohol/illegal drug abuse, hepatitis co-infection, or other
co-morbidities. 18FDG PET-CT specifically revealed vascular inflammation in the carotid arteries as a quantifiable source for molecular-level, pro-inflammatory events
that are biochemically related to early atherogenesis, and
if left unrestrained, can precipitate a CV event.
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18

FDG uptake (TBRmax)

3.0
2.5

Controls
HIV+ CVD

p= 0.03

p= 0.18

2.0

p= 0.02
1.5
1.0
0.5
0.0

Right
Carotid

Left
Carotid

findings reported here. Indeed, recent studies have
begun to investigate these questions using 18FDG PETCT [58].

Conclusion
Carotid 18FDG PET-CT imaging detected significant
vascular inflammation in HIV- infected men and women
with low Framingham CHD risk scores, suggesting that
this molecular imaging method is sensitive to early proatherosclerotic processes in a clinical population suspected of having chronic, low-grade inflammationinduced cardiovascular disease.

Aorta

Figure 2 Right and left carotid 18FDG uptake (Mean ± SE) was
greater (P < 0.03) in the HIV group (n = 9; 1.77 ± 0.26,
1.33 ± 0.09 target to background ratio-max (TBRmax)) than in
the control group (n = 5; 1.05 ± 0.10, 1.03 ±0.05 TBRmax). Aorta
18
FDG uptake tended (P = 0.18) to be greater in HIV (n = 5; 1.50 ±0.16
TBRmax) vs control group (n = 4; 1.24 ±0.05 TBRmax).

This study has limitations. We had a small sample size
and we may have been underpowered to detect certain
between group differences. But, these are expensive imaging studies, and therefore we intended these data to
show proof-of-principle for larger clinical studies. On
average, the HIV infected adults tended to be older than
the healthy controls. Advanced age is associated with
more vascular inflammation and 18FDG uptake. But, the
focus of this study was not on “what causes vascular inflammation in HIV?” Instead, the focus was on a dichotomous outcome; i.e., can we detect vascular
inflammation using 18FDG uptake in HIV with mild
CVD risk? The intent was not to address the question
“is vascular inflammation worse in age-matched HIV vs
healthy controls?” This is an excellent follow-up study,
now that we have developed the technique and we
understand the usefulness of 18FDG PET-CT imaging
for detecting early, low-level vascular inflammation in
people living with HIV. We did not attempt to quantify
18
FDG uptake in the coronary vessels; these are very
narrow, in motion, and surrounded by the glucoseconsuming heart muscle. Attempts to image inflammation in the coronary vessels using 18FDG have been
made [57]. We cannot determine the specific risk factor
that caused greater 18FDG uptake in HIV participants (e.
g., tobacco use, hypertension, glycemic control, higher
triglycerides) because the two groups were selected
based on their distinctly different cardiometabolic phenotypes. Likewise, the study was not designed to determine whether HIV-infection per se, or which specific
anti-HIV medication caused greater 18FDG uptake in the
HIV + participants. However, these pathogenesis questions can be addressed given the proof-of-principle
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